Fig. 2
From: KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumors
Validation of the predictive function of KMT2A/C mutations in the expanded ICI-treated cohort. a. Kaplan-Meier curves comparing the overall survival (OS) between the KMT2A/C-Mut group and the KMT2A/C-Wt group in the expanded ICI-treated cohort (n = 1395). mo, months; yr, years. Median OS and 2-year OS were also depicted. b. Forest plot depicting the OS benefit of KMT2A/C-Mut patients compared with KMT2A/C-Wt patients by cancer category. Bars represent the 95% CI